Home › Pain After Surgery › NCT07060495

RADA16 for Adult Tonsillectomy

Use of Novel Self-assembling RADA-16 Peptide Matrix to Decrease Postoperative Epistaxis for Tonsillectomy Surgeries

Who can join

Ages 18 and older · All sexes

Inclusion criteria:

Adults undergoing tonsillectomy (CPT codes)

Exclusion criteria:

Patients undergoing adenoidectomy or uvulopalatopharyngoplasty in addition to tonsillectomy

Patients who have had prior tonsillectomy or tonsillotomy

Patient undergoing tonsillectomy with concern for malignancy

Patients who are on opioids chronically prior to surgery

Patients with an additional indication for pain management (i.e. unrelated to tonsillectomy)

Patients who have been diagnosed with a bleeding disorder or hematologic malignancy

Patients who are on anticoagulants

The following at-risk populations:

Anyone under age 18

Pregnant women

Prisoners

Adults unable to consent (anyone lacking capacity)

About the study

The purpose of the research is to determine if RADA16 (also known as PuraStat®, PuraGel®, or PuraSinus®) improves patient outcomes following tonsillectomy procedures.

Researchers will compare application of device RADA16 to application of no device to see if RADA16 works to treat post tonsillectomy hemorrhage.

Participants will:

* Undergo tonsillectomy procedure. * Receive and fill out a survey sent via email every 2 days following their procedure for 15 days and track their symptoms.

What is being tested

• RADA16 hydrogel (device)

Sponsor: Rutgers, The State University of New Jersey · Participants: 134 · Started: Sep 12, 2025

Contact the study team

• Wayne D Hsueh, MD · Phone: 973-972-4588

Official record on ClinicalTrials.gov — NCT07060495

Locations in the U.S.

Conditions

• Pain After Surgery

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.